Skip to content

Clinical trials

Diabetes Mellitus trials in South Korea

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Diabetes Mellitus Country / region: South Korea Clear all

222 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20011
20031
20044
20051
20069
200714
200810
200920
201018
201120
20123
201316
201413
20159
20168
201714
20189
20194
20208
20214
20226
20237
20248
20259
20265

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed164
Unknown status26
Recruiting17
Terminated8
Not yet recruiting3
Active, not recruiting2
Enrolling by invitation1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Novo Nordisk A/S35
Seoul National University Bundang Hospital18
Seoul National University Hospital16
AstraZeneca13
Yonsei University12
Eli Lilly and Company9
Korea University Anam Hospital8
Samsung Medical Center7
Boryung Pharmaceutical Co., Ltd6
Hanmi Pharmaceutical Company Limited6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Diabetes Mellitus222
Diabetes Mellitus, Type 285
Hypertension14
Coronary Artery Disease11
Diabetes Mellitus, Type 110
Metabolic Diseases10
Insulin Resistance9
Dyslipidemias8
Obesity8
Glucose Metabolism Disorders6

Trials

Showing 1 to 25 of 222. Each trial links to its page on Pharma Observatory.

122 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.